This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
Estrogen Receptor alpha Monoclonal Antibody (1D5)
catalog :
MA5-13191
quantity :
500 µL
price :
US 646
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
1D5
reactivity :
African green monkey, human, mouse, rat, chicken, cat, domestic rabbit, rhesus macaque
application :
western blot, immunohistochemistry, immunocytochemistry, EMSA, immunohistochemistry - paraffin section
citations: 82
Published Application/Species/Sample/Dilution | Reference |
---|---|
| |
| |
| Cardoso R, Burns A, Moeller J, Skinner D, Padmanabhan V. Developmental Programming: Insulin Sensitizer Prevents the GnRH-Stimulated LH Hypersecretion in a Sheep Model of PCOS. Endocrinology. 2016;157:4641-4653 pubmed
|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| Einbond L, Soffritti M, Degli Esposti D, Tibaldi E, Lauriola M, Bua L, et al. Chemopreventive potential of black cohosh on breast cancer in Sprague-Dawley rats. Anticancer Res. 2012;32:21-30 pubmed
|
| |
| |
| |
| |
| |
| |
| Habib F, Zaki M, El Aal A, Safwat M, Domiaty M. Immunohistochemical expression of oestrogen and progesterone receptors during experimental acute and chronic murine Schistosomiasis mansoni. Rev Soc Bras Med Trop. 2010;43:531-5 pubmed
|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| Bueno de Mesquita J, Nuyten D, Wesseling J, VAN Tinteren H, Linn S, van de Vijver M. The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Ann Oncol. 2010;21:40-7 pubmed publisher
|
| |
| |
| |
| Ceausu M, Terzea D, Georgescu A, Dobrea C, Mihai M, Iosif C, et al. Transitional cell tumors of the ovary: a compact group with a heterogeneous histological and immunophenotypical pattern. Rom J Morphol Embryol. 2008;49:513-6 pubmed
|
| |
| |
| |
| |
| |
| Onal B, Levin R, Kogan B, Whitbeck C, Chichester P, Walebowa O, et al. The effect of maturation and age on oestrogen-induced functional hypertrophy of the female rabbit bladder. BJU Int. 2007;99:674-9 pubmed
|
| Singer C, Fink Retter A, Gschwantler Kaulich D, Thalhammer T, Hudelist G, Mueller R, et al. Selective spatial upregulation of intratumoral stromal aromatase in breast cancer patients: evidence for imbalance of local estrogen metabolism. Endocr Relat Cancer. 2006;13:1101-7 pubmed
|
| Schmidt M, Tollenaar R, de Kemp S, Broeks A, Cornelisse C, Smit V, et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol. 2007;25:64-9 pubmed
|
| Hannemann J, Kristel P, VAN Tinteren H, Bontenbal M, van Hoesel Q, Smit W, et al. Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer. 2006;95:1334-41 pubmed
|
| Wang M, Pan J, Song G, Chen H, An L, Qu S. Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters. Eur J Surg Oncol. 2007;33:195-201 pubmed
|
| Amant F, Woestenborghs H, Vandenbroucke V, Berteloot P, Neven P, Moerman P, et al. Transition of endometrial stromal sarcoma into high-grade sarcoma. Gynecol Oncol. 2006;103:1137-40 pubmed
|
| Rao K, Alper O, Opheim K, Bonnet G, Wolfe K, Bryant E, et al. Cytogenetic characterization and H-ras associated transformation of immortalized human mammary epithelial cells. Cancer Cell Int. 2006;6:15 pubmed
|
| Turbyville T, Wijeratne E, Liu M, Burns A, Seliga C, Luevano L, et al. Search for Hsp90 inhibitors with potential anticancer activity: isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran desert. J Nat Prod. 2006;69:178-84 pubmed
|
| Tse G, Tan P, Putti T, Lui P, Chaiwun B, Law B. Metaplastic carcinoma of the breast: a clinicopathological review. J Clin Pathol. 2006;59:1079-83 pubmed
|
| Wang R, Zhang H, Balasenthil S, Medina D, Kumar R. PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene. 2006;25:2931-6 pubmed
|
| Lipfert L, Fisher J, Wei N, Scafonas A, Su Q, Yudkovitz J, et al. Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylation. Mol Endocrinol. 2006;20:516-33 pubmed
|
| Saylam G, Yücel O, Sungur A, Onerci M. Proliferation, angiogenesis and hormonal markers in juvenile nasopharyngeal angiofibroma. Int J Pediatr Otorhinolaryngol. 2006;70:227-34 pubmed
|
| Saglam E, Usubutun A, Kart C, Ayhan A, Kucukali T. Reactive nodular fibrous pseudotumor involving the pelvic and abdominal cavity: a case report and review of literature. Virchows Arch. 2005;447:879-82 pubmed
|
| Akhan S, Yavuz E, Tecer A, Iyibozkurt C, Topuz S, Tuzlali S, et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecol Oncol. 2005;99:36-42 pubmed
|
| Wittmann B, Fujinaga K, Deng H, Ogba N, Montano M. The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor cyclin T1. Oncogene. 2005;24:5576-88 pubmed
|
| Dinulescu D, Ince T, Quade B, Shafer S, Crowley D, Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med. 2005;11:63-70 pubmed
|
Flötotto T, Niederacher D, Hohmann D, Heimerzheim T, Dall P, Djahansouzi S, et al. Molecular mechanism of estrogen receptor (ER)alpha-specific, estradiol-dependent expression of the progesterone receptor (PR) B-isoform. J Steroid Biochem Mol Biol. 2004;88:131-42 pubmed
| |
Guler G, Uner A, Guler N, Han S, Iliopoulos D, Hauck W, et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer. 2004;100:1605-14 pubmed
| |
Kapucuoglu N, Coban T, Raunio H, Pelkonen O, Edwards R, Boobis A, et al. Expression of CYP3A4 in human breast tumour and non-tumour tissues. Cancer Lett. 2003;202:17-23 pubmed
| |
Beliakoff J, Bagatell R, Paine Murrieta G, Taylor C, Lykkesfeldt A, Whitesell L. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res. 2003;9:4961-71 pubmed
| |
Wittmann B, Wang N, Montano M. Identification of a novel inhibitor of breast cell growth that is down-regulated by estrogens and decreased in breast tumors. Cancer Res. 2003;63:5151-8 pubmed
| |
Wang H, Mahadevappa M, Yamamoto K, Wen Y, Chen B, Warrington J, et al. Distinctive proliferative phase differences in gene expression in human myometrium and leiomyomata. Fertil Steril. 2003;80:266-76 pubmed
| |
Bethea C, Lu N, Reddy A, Shlaes T, Streicher J, Whittemore S. Characterization of reproductive steroid receptors and response to estrogen in a rat serotonergic cell line. J Neurosci Methods. 2003;127:31-41 pubmed
| |
Hudelist G, Czerwenka K, Kubista E, Marton E, Pischinger K, Singer C. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator. Breast Cancer Res Treat. 2003;78:193-204 pubmed
| |
Seth P, Porter D, Lahti Domenici J, Geng Y, Richardson A, Polyak K. Cellular and molecular targets of estrogen in normal human breast tissue. Cancer Res. 2002;62:4540-4 pubmed
| |
Suzuki T, Darnel A, Akahira J, Ariga N, Ogawa S, Kaneko C, et al. 5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. J Clin Endocrinol Metab. 2001;86:2250-7 pubmed
| |
El Khissiin A, Journe F, Laios I, Seo H, Leclercq G. Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells. Steroids. 2000;65:903-13 pubmed
| |
Lu N, Shlaes T, Gundlah C, Dziennis S, Lyle R, Bethea C. Ovarian steroid action on tryptophan hydroxylase protein and serotonin compared to localization of ovarian steroid receptors in midbrain of guinea pigs. Endocrine. 1999;11:257-67 pubmed
|
product information
Product Type :
Antibody
Product Name :
Estrogen Receptor alpha Monoclonal Antibody (1D5)
Catalog # :
MA5-13191
Quantity :
500 µL
Price :
US 646
Clonality :
Monoclonal
Purity :
Protein G
Host :
Mouse
Reactivity :
Human
Applications :
Immunocytochemistry: 1:500-1:1000, Immunofluorescence: 1:500-1:1000, Immunohistochemistry (Paraffin): 0.4-0.8 µg/mL, Western Blot: 0.5-1.0 µg/mL
Species :
Human
Clone :
1D5
Isotype :
IgG1, kappa
Storage :
4° C
Description :
Estrogen Receptors (ER) are members of the steroid/thyroid hormone receptor superfamily of nuclear receptors. The estrogen receptor is a ligand-activated transcription factor, that when bound to estrogen hormone, induces a conformational change that allows dimerization and binding to estrogen response elements (ERE) in DNA. When bound to EREs, ER can positively or negatively regulate gene transcription through the recruitment of coactivator or corepressor proteins. There are two different forms of the estrogen receptor, alpha and beta, encoded by separate genes (ESR1 and ESR2, respectively). Due to alternative RNA splicing, at least 4 estrogen receptor-alpha isoforms are known to exist (Isoform 1 (66 kDa), Isoform 2 (53 kDa), Isoform 3 (47 kDa), Isoform 4 (35 kDa)). Estrogen receptors are widely expressed in different tissue types and are essential for sexual development and reproductive function. They also play a role in other tissues such as bone. Estrogen receptors are involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis.
Immunogen :
Recombinant human estrogen receptor protein
Format :
Liquid
Applications w/Dilutions :
Immunocytochemistry: 1:500-1:1000, Immunofluorescence: 1:500-1:1000, Immunohistochemistry (Paraffin): 0.4-0.8 µg/mL, Western Blot: 0.5-1.0 µg/mL
Aliases :
DKFZp686N23123; ER; Er alpha; ER36; ERa; ERALPHA; ER-alpha; ESR; esr 1; Esr1; esr-1; ESRA; Estr; Estra; estradiol receptor; estrogen nuclear receptor alpha; estrogen receptor; estrogen receptor 1; estrogen receptor 1 (alpha); estrogen receptor alpha; estrogen receptor alpha c-terminus splice variant 1-2; estrogen receptor alpha E1-E2-1-2; estrogen receptor alpha E1-N2-E2-1-2; estrogen receptor alpha splice variant, CTERP-1; estrogen receptor alpha splice variant, ERalphaDup5; estrogen receptor alpha splice variant, ERalphai45a; estrogen receptor alpha splice variant, ERalphai45bL; estrogen receptor alpha splice variant, ERalphai45bS; estrogen receptor alpha splice variant, ERalphai45c; estrogen receptor alpha splice variant, ERalphai56; estrogen receptor alpha splice variant, ERalphai67; estrogen receptor alpha variant delta 4; estrogen receptor alpha-like; estrogen receptor protein; estrogen receptor, alpha; ESTRR; hER-alpha36; I79_001166; LOC100351261; Nr3a1; nuclear receptor; Nuclear receptor subfamily 3 group A member 1; RNESTROR; RP1-130E4.1
company information

Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments